What is Rezurock’s (belumosudil) market share in Canada in 2025?
No market-share figures for Rezurock specifically in Canada in 2025 are provided in the available information, so a precise percentage cannot be stated.
Where would Sanofi/Rezurock market-share data for Canada typically come from?
Canadian brand-level market share is usually estimated from prescription or dispensed-unit sources (depending on the dataset provider), such as pharmacy claims databases, IQVIA-style sales/claims reporting, or public drug utilization reporting where available. If you can share the source you’re using (e.g., IQVIA country report, provincial/insurer utilization extract, or a specific article), I can help interpret it or reconcile differences.
Is Rezurock considered a “high share” product in oncology/IMiDs/JAK-classes in Canada?
Rezurock is not generally categorized alongside high-volume oncology brands in the way broader chemotherapy and supportive-care drugs often are, but whether it has high or low share in Canada depends on the specific market definition (all oncology prescriptions vs. the narrower indication/population eligible for belumosudil). Without a cited dataset, any claim about “high share” would be speculative.
Why “market share in 2025” can vary by definition
Different reports can give different answers for the same product because of:
- Whether the market is defined by prescriptions, prescription equivalents, units dispensed, or dollar sales.
- Whether it counts only branded products or includes generics/biosimilars in the denominator.
- Whether the timeframe is calendar year 2025 or trailing 12 months.
- Whether the analysis is by total Canadian market vs. a narrow therapeutic area or indication.
How to get an exact Canada 2025 figure
To produce an exact market-share number for Rezurock in Canada in 2025, you’ll need at least one of the following:
- A link or excerpt from the market-share report/article you’re referencing (showing the exact percentage), or
- The underlying sales/dispensed-unit totals for Rezurock and the total market denominator used by the report.
If you paste the text (or share the link) you have, I can extract the Canada 2025 market share and explain what the denominator and methodology were.
Which competitors affect Rezurock’s share in Canada?
Rezurock competes within the broader space of therapies used for relevant immune-mediated indications, but the direct “share” impact depends on which line of therapy and which eligible patient pool you’re using as the market definition. Exact competitor mapping and comparative share requires the same dataset or report definition.
---
Sources
No sources were provided with your question, and no market-share dataset for Rezurock in Canada in 2025 was included in the available information.